Amanta Healthcare Q4 Results Preview: Earnings Growth, Key Expectations & Outlook
Updated: 20 Mar 2026 • 7:25 pm
Posted by:
Amanta Healthcare Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Amanta Healthcare was listed on the National Stock Exchange (NSE) on 09-Sep-2025. Amanta Healthcare share has its face value of 10 per share, and its NSE symbol is AMANTA. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.
Amanta Healthcare Q4 Results 2026 Preview
- Amanta Healthcare Q4 FY26 revenue is expected to be around Stable Performance, representing a 7-10% YoY increase compared to the same quarter last year.
- Profit After Tax, or PAT, is projected to rise 8-12% YoY.
- EBITDA to rise 7-10%.
- Amanta Healthcare is expected to show Stable Performance in its revenue.
Click and Sign Up to Get Live Updates on Q4 Results
Amanta Healthcare Share Performance
- Over the past six months, Amanta Healthcare share price has Up by 16% to 97.93.
- Moreover, over the past year, the stock has Up by 28%
- Despite this weak short-term performance, Amanta Healthcare stock has delivered a financially sound 140% return over the past 5 years.
- As of today, 20-03-2026, the Amanta Healthcare share price is trading at 97.93 per share.
Key Factors to Watch for Amanta Healthcare Q4 Results FY26
- Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
- Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
- Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
- Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
- Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.
About Amanta Healthcare
Amanta Healthcare is a pharmaceutical company specializing in sterile injectables, infusion therapy, and medical devices, supplying hospitals and healthcare institutions in India and over 70 countries, with a focus on quality manufacturing and global exports.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Final Thoughts
Amanta Healthcare is gear up to announce its Q4 FY26 results. Analysts expect 7-10% revenue growth, a 8-12% rise in PAT, and a 7-10% rise in EBITDA. Amanta Healthcare focuses on revenue growth from order execution, margin improvement, a strong order book, and management.
Stay informed with Univest blogs to get real-time updates on Amanta Healthcare Q4 results FY26.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
Siemens Energy Q4 FY26 Earnings Preview Expectations Outlook
Entertainment Network Q4 FY26 Earnings Preview Outlook
Energy Development Q4 FY26 Earnings Preview Outlook
Endurance Technologies Q4 FY26 Earnings Preview Expectations Outlook
Recent Articles
Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
30 October 2026
Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
30 October 2026
Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
30 October 2026
Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
30 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
Asian Paints Share Price After Q2 Results: Profit Up 7%, but Price Hikes Are Yet to Brighten Margins
Popular this week
Borosil Share Price Jumps 16% After Strong Q2 Results: Record Profit, Margin Jump and Key Price Levels to Know
Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times